会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • TREATMENT OF METASTATIC PROSTATE CANCER
    • 治疗前列腺癌
    • WO2015065919A1
    • 2015-05-07
    • PCT/US2014/062455
    • 2014-10-27
    • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    • GAO, Allen C.LIU, ChengfeiLOU, Wei
    • A61K38/00A61K31/40A61K38/17C07K14/54A61K31/165
    • G01N33/57434A61K31/277A61K31/337A61K31/405A61K31/4166A61K31/58A61K31/609A61K38/00A61K45/06A61K47/6869C12Q1/6886C12Q2600/178G01N2800/52A61K2300/00
    • The present invention provides new compositions and methods for treating prostate cancer, e.g ., drug-resistant prostate cancer, such as anti-androgen drug ( e.g ., enzalutamide) resistant and/or castration resistant prostate cancer (CRPC). These new compositions include, but are not limited to, pharmaceutical compositions that include an AR-V7 inhibitor, such as niclosamide. Alternatively, these new compositions can include, but are not limited to, pharmaceutical compositions that include an AKR1C3 inhibitor, such as indomethacin. These new methods include, but are not limited to, methods of administering an AR-V7 inhibitor, such as niclosamide, and/or an AKR1C3 inhibitor, such as indomethacin, to treat patients having prostate cancer. The present invention also provides methods of inhibiting androgen receptor variant expression, e.g. AR-V7, and methods of killing cells expressing AR-V7. The present invention further provides methods of inhibiting AKR1C3 expression or activity, and methods of killing cells that express AKR1C3.
    • 本发明提供了用于治疗前列腺癌的新组合物和方法,例如耐药前列腺癌,例如抗雄激素药物(例如恩扎洛胺)和/或抗阉割性前列腺癌(CRPC)。 这些新的组合物包括但不限于包含AR-V7抑制剂如氯硝柳胺的药物组合物。 或者,这些新组合物可以包括但不限于包含AKR1C3抑制剂如吲哚美辛的药物组合物。 这些新方法包括但不限于施用AR-V7抑制剂如氯硝柳胺和/或AKR1C3抑制剂如吲哚美辛的方法来治疗患有前列腺癌的患者。 本发明还提供了抑制雄激素受体变体表达的方法,例如, AR-V7,以及杀死表达AR-V7细胞的方法。 本发明还提供抑制AKR1C3表达或活性的方法,以及杀死表达AKR1C3的细胞的方法。